Evinacumab
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Homozygous Familial Hypercholesterolemia
Conditions
Homozygous Familial Hypercholesterolemia
Trial Timeline
Jun 29, 2020 → May 30, 2023
NCT ID
NCT04233918About Evinacumab
Evinacumab is a phase 3 stage product being developed by Regeneron Pharmaceuticals for Homozygous Familial Hypercholesterolemia. The current trial status is completed. This product is registered under clinical trial identifier NCT04233918. Target conditions include Homozygous Familial Hypercholesterolemia.
What happened to similar drugs?
1 of 16 similar drugs in Homozygous Familial Hypercholesterolemia were approved
Approved (1) Terminated (0) Active (15)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06500598 | Pre-clinical | Completed |
| NCT04863014 | Phase 2 | Terminated |
| NCT04233918 | Phase 3 | Completed |
| NCT03409744 | Phase 3 | Completed |
Competing Products
20 competing products in Homozygous Familial Hypercholesterolemia